News | May 23, 2026
Gujarat Themis Biosyn acquires MicroBiopharm Japan for Rs. 1,300 Cr
Transition to a fermentation-based globally integrated CDMO platform
Transition to a fermentation-based globally integrated CDMO platform
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
This is used to treat central diabetes insipidus and bedwetting
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Subscribe To Our Newsletter & Stay Updated
